(NASDAQ:RLYB) NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it received an equity milestone payment of $12.5 million from Recursion. The milestone payment was triggered by the initiation of additional preclinical studies for REV102, an investigational ENPP1 inhibitor in development for the treatment of hypophosphatasia
Related Questions
How will the $12.5 million equity milestone affect Rallybio’s cash runway and near‑term valuation?
What is the expected timeline and cost structure for the additional pre‑clinical studies of REV102, and how might that influence future milestone payments?
How does Rallybio’s partnership with Recursion compare to similar biotech collaborations, and what does it suggest about the competitive positioning of REV102 in the rare‑disease market?